Catalog No.
RHC90505
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000
Target
Cell division protein kinase 4, PSK-J3, Cyclin-dependent kinase 4, CDK4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11802
Applications
ELISA, FCM, IF, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3C70
Antibody-mediated ratiometric delivery of FLT3 and CDK4/6 dual inhibitors for targeted treatment of acute myeloid leukemia., PMID:40482924
Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer., PMID:40449480
Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes., PMID:40439885
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer., PMID:40386501
Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy., PMID:40385566
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium., PMID:40340127
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment., PMID:40287441
The treatment of breast cancer in the era of precision medicine., PMID:40269562
Therapy of early breast cancer: current status and perspectives., PMID:40261372
Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient., PMID:40259166
Desmoplastic small round cell tumor: an update of current management practices., PMID:40254671
Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer., PMID:40163189
Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report., PMID:40110580
Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?, PMID:40075731
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer., PMID:40010764
Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis., PMID:40006075
A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy., PMID:40005476
Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline., PMID:40002228
First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis., PMID:39969377
Implication of TRPM8, CD47, and CDK4 expressions in hepatocellular carcinoma progression., PMID:39957041
[A Case of a Patient with Hormone-Positive HER2-Negative Breast Cancer Whose Multiple Brain Metastases Disappeared after Abemaciclib Combination Therapy]., PMID:39948886
Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future., PMID:39900320
RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032
The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer., PMID:39747865
Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer., PMID:39664178
Ribociclib-Induced Autoimmune Hepatitis: A Case Report., PMID:39559679
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion., PMID:39534582
Updates in Treatment of HER2-positive Metastatic Breast Cancer., PMID:39520520
Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer., PMID:39487929
Current landscape of targeted therapy in esophageal squamous cell carcinoma., PMID:39454516
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer., PMID:39433229
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma., PMID:39405335
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis., PMID:39373732
IMP3, CDK4, MDM2 and β-catenin expression in Enchondroma and Central Chondrosarcoma: Diagnostic and prognostic utility., PMID:39368400
Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer., PMID:39218402
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024., PMID:39184927
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer., PMID:39179659
p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells., PMID:39103548
Systemic Therapy in Breast Cancer., PMID:39013124
Revised Diagnosis From Histiocytic Neoplasm to Optic Chiasm Glioblastoma After Genetic Analysis., PMID:38926909
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer., PMID:38884028
Case report: Pilomatrix carcinoma with PDL1 expression and CDKN2A aberrant., PMID:38873609
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer., PMID:38854937
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments., PMID:38838928
GPR168 functions as a tumor suppressor in mouse melanoma by restraining Akt signaling pathway., PMID:38805406
Current Status and Future Perspectives of Antibody-Drug Conjugates in Hormone Receptor-Positive Breast Cancer., PMID:38791880
The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)., PMID:38779868
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer., PMID:38772169
For research use only. Not for human or drug use.
